52-week interim results from phase 2b cohort of PRISM study, using 4D-150 for the treatment of patients with wet age-related macular degeneration, expected in February of 2025. Initiation of phase 3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback